Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study

Judith Neukirchen; Michael Lauseker; Sabine Blum; Aristoteles Giagounidis; Michael Lübbert; Samuela Martino; Sergio Siragusa; Richard F Schlenk; Uwe Platzbecker; Wolf-Karsten Hofmann; Katharina Götze; Giuseppe A Palumbo; Silvana Magrin; Andrea Kündgen; Carlo Aul; Barbara Hildebrandt; Joerg Hasford; Guido Kobbe; Rainer Haas; Ulrich Germing

doi:10.1016/j.leukres.2013.10.013

Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study

Leuk Res. 2014 Jan;38(1):57-64. doi: 10.1016/j.leukres.2013.10.013. Epub 2013 Oct 26.

Authors

Judith Neukirchen¹, Michael Lauseker², Sabine Blum³, Aristoteles Giagounidis⁴, Michael Lübbert⁵, Samuela Martino⁶, Sergio Siragusa⁶, Richard F Schlenk⁷, Uwe Platzbecker⁸, Wolf-Karsten Hofmann⁹, Katharina Götze¹⁰, Giuseppe A Palumbo¹¹, Silvana Magrin¹², Andrea Kündgen¹³, Carlo Aul⁴, Barbara Hildebrandt¹⁴, Joerg Hasford², Guido Kobbe¹³, Rainer Haas¹³, Ulrich Germing¹³

Affiliations

¹ Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany. Electronic address: Judith.Neukirchen@med.uni-duesseldorf.de.
² Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany.
³ Department of Hematology, University Lausanne, Switzerland.
⁴ Department of Hematology, Oncology and Clinical Immunology, St. Johannes Hospital, Duisburg, Germany.
⁵ Department of Hematology and Oncology, Albert-Ludwigs-University, Freiburg, Germany.
⁶ Department of Hematology, University of Palermo, Italy.
⁷ Department of Internal Medicine III, University Hospital Ulm, Germany.
⁸ Department of Medicine 1, University Hospital Carl Gustav Carus, Dresden, Germany.
⁹ Department of Medicine III, University Hospital Mannheim, Germany.
¹⁰ Department of Medicine III, Division for Hematology and Oncology, Klinikum rechts der Isar, Technical University, Munich, Germany.
¹¹ Department of Hematology, AOU "Policlinico - V. Emanuele", Catania, Italy.
¹² Division of Hematology and BMT Unit, V. Cervello Hospital, Palermo, Italy.
¹³ Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany.
¹⁴ Department of Human Genetics, Heinrich-Heine-University, Düsseldorf, Germany.

PMID: 24238640
DOI: 10.1016/j.leukres.2013.10.013

Abstract

The revised IPSS (IPSS-R) was developed aiming at a better prognostication, taking into account patients treated with best supportive care. We herein validated this model on the basis of data from 1314 patients who received BSC only as well as patients who underwent induction chemotherapy (n=214) or allogeneic transplantation (n=167). We could demonstrate a clear distinction of the IPSS-R risk categories with regard to survival and risk of AML evolution in all patient cohorts. When comparing IPSS-R, IPSS, WHO prognostic scoring system (WPSS) and Duesseldorf score, the best results regarding the ability to predict survival were obtained by the IPSS-R.

Keywords: IPSS; IPSS-R; MDS; Prognosis; Survival; WPSS.

Publication types

Multicenter Study
Validation Study

MeSH terms

Acute Disease
Adolescent
Adult
Aged
Aged, 80 and over
Disease Progression
Female
Humans
Leukemia, Myeloid / pathology
Leukemia, Myeloid / therapy*
Male
Middle Aged
Multivariate Analysis
Myelodysplastic Syndromes / pathology
Myelodysplastic Syndromes / therapy*
Prognosis
Reproducibility of Results
Risk Assessment / methods*
Risk Factors
Survival Analysis
Young Adult